Multiple Myeloma: Update from ASH. Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School
|
|
- George Armstrong
- 6 years ago
- Views:
Transcription
1 Multiple Myeloma: Update from ASH Kenneth C. Anderson, M.D. Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer Institute Harvard Medical School
2 Integration of Novel Therapy Into Myeloma Management Bortezomib, Lenalidomide, Thalidomide, Doxil, Carfilzomib Target MM in the BM microenvironment to overcome conventional drug resistance in vitro and in vivo Effective in relapsed/refractory, relapsed, induction, consolidation, and maintenance therapy Eight FDA approvals and median survival prolonged from 3-4 to 6-7 years, with additional prolongation from maintenance New approaches needed to treat and ultimately prevent relapse Combinations in the Upfront Treatment of MM Stewart AK, Richardson PG, San Miguel JF Blood 2009
3 Summary of ASH Use of novel agents as initial, maintenance, and relapsed/refractory MM therapy 2. Second generation proteasome inhibitors and immunomodulatory drugs 3. Development of novel combination therapies 4. Monoclonal antibody therapies 5. Treatment of side effects Impact of Novel Agents in the Treatment of Elderly Pts with Newly Diagnosed MM Substantial improvements in PFS and OS Median PFS (mos) Median OS (mos) MP MPT VMP 7,8, % (3-yr OS)* MPR-R 9 31 N/A VMP-VT/VP % (3-yr OS)* VMPT-VT % (3-yr OS)* *Median OS not reached N/A: not available 1 Palumbo et al. Blood 2008; 112: Facon et al. Lancet 2007; 370: Hulin et al. J Clin Oncol 2009; 27: Waage et al. Blood 2010; 116: Wijermans et al. J Clin Oncol 2010; 28: Beksac et al. Eur J Haematol 2011;86: San Miguel et al. N Engl J Med 2008; 359(9): ; Supplementary Appendix 8 Mateos et al. J Clin Oncol 2010; 28(13): Palumbo et al. ASH 2010 (Abstract 622) 10 Mateos et al. Lancet Oncol 2010; 11(10): Palumbo et al. ASH 2010 (Abstract 620)
4 Treatment schedule 511 patients (older than 65 years) randomized from 58 Italian centers Patients: Symptomatic multiple myeloma/end organ damage with measurable disease 65 yrs or <65 yrs and not transplant-eligible; creatinine 2.5 mg/dl R A N D O M I Z E VMP Cycles 1-9 Bortezomib 1.3 mg/m 2 IV: days 1,8,15,22* Melphalan 9 mg/m 2 and prednisone 60 mg/m 2 days x 5-week cycles in both arms VMPT Cycles 1-9 Bortezomib 1.3 mg/m 2 IV: days 1,8,15,22* Melphalan 9 mg/m 2 and prednisone 60 mg/m 2 days 1-4 Thalidomide 50 mg/day continuously NO MAINTENANCE Until relapse MAINTENANCE Bortezomib 1.3 mg/m 2 IV: days 1,15 Thalidomide 50 mg/day continuously * 66 VMP patients and 73 VMPT patients were treated with twice weekly infusions of Bortezomib Conclusion VMPT-VT VMP P value 5-year PFS 29% 13% < year TNT 41% 19% < year OS 61% 51% year OS from relapse 47% 46% 0.63 P a
5 Treatment discontinuation VMPT VT VMP Discontinuation rate a, % years of age > 75 years of age Bortezomib dose intensity, % years of age > 75 years of age a Discontinuation due to AEs Palumbo et al ASH 2013 Abstr 200 Carfilzomib: A Novel Proteasome (Chymotryptic) Inhibitor Novel chemical class with highly selective and irreversible proteasome binding Tetrapeptide Improved antitumor activity with O consecutive day dosing N O H N O N H O H N O N H O O No neurotoxicity in animals Epoxyketone Durable responses in relapsed and relapsed/ refractory MM w/o neuropathy led to accelerated FDA approval in July 2012 Carfilzomib lenalidomide Dex versus lenalidomide Dex phase III trial for full drug approval
6 VTD Consolidation post-asct Study details n=39 in VGPR after ASCT 1 treated with 4 cycles VTD Molecular substudy of GIMEMA trial: VTD vs TD induction and consolidation 2 n=67 with ncr after ASCT, treated with two 35-d cycles VTD or TD Results Median follow up: 42 mos: No relapse in pts with molecular remission Significant increase in molecular remissions and reduction in tumor burden with VTD versus TD n=46 PR after HDM 3 treated with 2 cycles vtd (bortezomib 1mg/m 2 twice/wk, thal 100 mg/d, dex 40 mg/d once/wk) Improvement of response in 39% postconsolidation 1 Ladetto et al. J Clin Oncol 2010; 28(12): Terragna et al. Haematologica 2011; 96 (s1): S96 (Abstract P-224); poster presentation at IMW Roussel et al. ASH 2010 (Abstract 3041), poster presentation Carfilzomib, Thalidomide and Dexamethasone (CTd) for induction and consolidation in transplant for MM Induction Intensification Consolidation Carfilzomib 20/27mg/m 2 days 1,2,8,9,15,16 of a 28 day cycle. HDM Carfilzomib 27mg/m 2 days 1,2,8,9,15,16 of a 28 day cycle. Thalidomide 200 mg days 1-28 of a 28 day cycle Dexamethasone 40 mg days 1,8,15,21 of a 28 day cycle Stem Cell Harvest 200m g/m 2 ASCT Thalidomide 50 mg days 1-28 of a 28 day cycle Dexamethasone 40 mg days 1,8,15,21 of a 28 day cycle 4 cycles. 4 cycles. Sonneveld et al ASH 2013 Abstr 333
7 Cumulative Response (%) response (%) CR VGPR PR 0 Induction HDM/ASCT Consolidation Sonneveld et al ASH 2013 Abstr 333 Conclusions CTd is feasible and tolerable and effective Response is rapid and increases with HDM/ASCT and consolidation High CR (44 %), also in high-risk patients PNP only grade 1+2, mostly Thalidomide related Successful stem cell harvest in all eligible patients Longer follow-up needed for PFS and OS Dose level 20/36 mg/m 2 was completed per 10/2012 Dose level 20/45 mg/m 2 will start 12/2012
8 CYCLONE Initial Therapy in MM Agent Dose Level Route Day Rx Carfilzomib See Phase I and II dosing (15-45 mg/m 2 ) IV 1,2,8,9,15,16 Every 28 days Thalidomide 100mg PO 1-28 Every 28 days Cyclophosphamide 300mg/m 2 PO 1,8,15 Every 28 days Dexamethasone 40mg PO 1,8,15,22 Every 28 days Mikhael et al ASH 2013 Abstr 445 CYCLONE (carfilzomib, cyclophosphamide, thalidomide and dexamethasone) Initial Therapy in MM 1. is highly effective with ORR 96% and VGPR 74% in only 4 cycles 2. CYCLONE is well tolerated, with manageable myelosuppression and no > Grade 1 neuropathy 3. Patients can successfully collect stem cells 4. MTD has been reached at carfilzomib 20/36 mg/m 2 Mikhael et al ASH 2013 Abstr 445
9 Carfilzomib Lenalidomide Dexd in Newly Diagnosed MM *Jakubowiak et al. study Our study Phase I/II, n=53 Phase II, n=45 Combination Therapy CRd (Phase II Cfz 20/36 mg/m 2 ) 8 cycles CRd (Cfz 20/36 mg/m 2 ) 8 cycles Extended dosing CRd (CFZ every other week) 16 cycles Off protocol Rev 25 mg D1-21 after 16 cycles Rev 10 mg D cycles Transplant > PR stem cell collection HDM optional Stem cell collection Correlatives Flow cytometry MRD Flow cytometry MRD (3-4 x 10 6 ) PET-CT Proteasome assays GEP Whole genome sequencing * Jakubowiak A. et al., Blood, 2012; 120(9): Korde et al ASH 2013 Abstr 732 Carfilzomib, Lenalidomide, and Dex in Newly Diagnosed MM Among first 20 patients, no > grade 3 neuropathy Rapid and deep responses; median time to scr: 4.5 cycles (range: 2-7) Best response (median 7 cycles) ncr/scr = 75% ORR (PR or better) = 95% Among 10 ncr/scr patients assessed by flow cytometry, all were MRD negative PET/CT improved Korde et al ASH 2013 Abstr 732
10 MLN2238/9708 Oral Chymotryptic Inhibitor More Potently Blocks MM Cell Growth In Vivo than Bortezomib Clinical Trials Ongoing in Relapsed/Refractory MM and with Lenalidomide Dex as Initial Therapy Chauhan et al., Clin Cancer Res 2011; 17: Phase 1/2 study of MLN9708 lenalidomide and dex in patients with previously untreated MM Induction: up to 12 x 28-day treatment cycles Maintenance MLN9708 MLN9708 MLN9708 MLN9708 Dex 40 mg Dex 40 mg Dex 40 mg Dex 40 mg maintenance Lenalidomide 25 mg, days 1 21 Days 1, 8, day cycles Phase 1: oral MLN9708 dose-escalation Phase 2: oral MLN9708 at the RP2D from phase 1 Stem cell collection allowed after 3 cycles, with autologous stem cell transplantation (ASCT) deferred until after 6 cycles MLN9708 maintenance continued until progression or unacceptable toxicity Mandatory thromboprophylaxis with aspirin or low-molecular-weight heparin Kumar et al ASH 2013 Abstr 332
11 Phase 1/2 study of MLN9708 lenalidomide and dex in patients with previously untreated MM Oral weekly MLN9708, lenalidomide, and dexamethasone is well tolerated incidence of PN has been limited At median drug exposure of 6 months, 92% PR or better, including VGPR 55% and CR 23% Responses increased with number of cycles and deepened over time 88% of patients achieving CR who were evaluable for MRD status were confirmed as MRD-negative A phase 3 trial of MLN9708 plus lenalidomide dexamethasone versus placebo plus lenalidomide dexamethasone in patients with relapsed and/or refractory MM is currently enrolling (NCT ) for new drug approval Kumar et al ASH 2013 Abstr 332 CALGB Schema Registration Restaging Days Randomization D S Stage 1 3, < 70 years > 2 cycles of induction Attained SD or better 1 yr from start of therapy > 2 x 10 6 CD34 cells/kg Mel 200 ASCT McCarthy et al NEJM 2012; 366: 1770 CR PR SD Placebo Lenalidomide* 10 mg/d with (5 15 mg) * provided by Celgene Corp, Summit, NJ
12 CALGB , 10/31/2011 McCarthy et al NEJM 2012; 366: 1770 ITT Analysis with a median follow up from transplant of 34 months. P < Estimated HR=0.48 (95% CI = 0.36 to 0.63), Median TTP: 46 months versus 27 months. CALGB , 10/31/2011 McCarthy et al NEJM 2012; 366 : 1770 Median follow up of 34 months There are 35 deaths in the lenalidomide arm and 53 deaths in the placebo arm. P = 0.028
13 IFM : Risk Factors for Second Malignancies (n= 582) Factors (Multivariate Analysis) P value Treatment arm (Placebo vs Rev) 0.01 Age (<=55 y vs >55 years) 0.01 Sex (M vs F) 0.01 ISS (I +II vs III) 0.01 Induction with DCEP (Yes vs No) 0.02 Atal et al NEJM 2012 Progression-Free and Overall Survival All Patients Median PFS 4-year OS MPR-R 31 months MPR-R 59% MPR 14 months MPR 58% 100 MP 13 months 100 MP 58% 26 Patients (%) HR P <.001 HR P =.135 Patients (%) HR P =.648 HR P = Time (Months) Time (Months) TTP HR advantages were similar: MPR-R vs MP = 0.337; MPR vs MP = HR, hazard ratio; MP, melphalan, prednisone; MPR, melphalan, prednisone, lenalidomide; MPR-R, melphalan, prednisone, lenalidomide with lenalidomide maintenance; OS, overall survival; PFS, progression-free survival; TTP, time to progression.
14 Second Primary Malignancies All Patients PD/Death Hematologic SPM Solid Tumor MPR-R 100 MPR 100 MP Patients (%) Time (Months) Time (Months) Time (Months) SPM, n (IR per 100 per year) MPR-R MPR MP (n = 150) (n = 152) (n = 153) Total Invasive SPMs 12 (3.04) 10 (2.57) 4 (0.98) Hematologic 7 (1.75) 6 (1.54) 1 (0.24) Solid tumors 5 (1.26) 5 (1.28) 3 (0.74) Non-melanoma skin cancer 2 (0.50) 5 (1.29) 6 (1.50) IR, incidence rate; MP, melphalan, prednisone; MPR, melphalan, prednisone, lenalidomide; MPR-R, melphalan, prednisone, lenalidomide with lenalidomide maintenance; PD, progressive disease; PY, person-year; SPM, second primary malignancy. GEM05MENOS65 De novo symptomatic MM <65 yrs 1st randomization VBMCP/VBAD x 4 + BORTEZOMIB x 2 THALIDOMIDE/ DEXAMETHASONE x 6 THAL/DEX/ BORTEZOMIB x 6 ASCT (MEL200) 2nd randomization INTERFERON- 2b* (IFN) x 3 yrs THALIDOMIDE** (Thal) x 3 yrs THALIDOMIDE/BORTEZOMIB & (TV) x 3 yrs *3 MU/sc 3 times a week Rosinol ASH 2012 Abstr 3334 **100 mg/day & Thal 100 mg/day. Bortezomib 1.3 mg/m2 days 1,4,8,11 every 3 months
15 Conclusions The addition of bortezomib to thalidomide maintenance resulted in a significantly longer PFS when compared with thalidomide alone or with alfa2 IFN, with no increased toxicity. Discontinuations due to progressive disease were significantly higher with interferon while the single agent thalidomide arm resulted in a higher rate of discontinuations due to toxicity. Finally, the benefit of bortezomib was only observed in patients with good risk cytogenetics. Rosinol ASH 2012 Abstr 3334 Pomalidomide in Myeloma C MM cells IL-6 A B ICAM-1 TNF IL-1 Bone Marrow Stromal Cells D VEGF bfgf Hideshima et al. Blood 96: 2943, 2000 Davies et al. Blood 98: 210, 2001 Gupta et al. Leukemia 15: 1950, 2001 Bone Marrow Vessels Dendritic Cells NFAT PKC PI3K CD8+ T Cells IL-2 CD28 IL-2 IFN E NK Cells NK-T Cells Mitsiades et al. Blood 99: 4525, 2002 Lentzsch et al Cancer Res 62: 2300, 2002 LeBlanc R et al. Blood 103: 1787, 2004 Hayashi T et al. Brit J Hematol 128: 192, 2005
16 Pomalidomide With Low-Dose Dexamethasone Relapsed and Refractory Multiple Myeloma POM was effective in heavily pretreated patients who had already received LEN and bortezomib and who progressed on their last line of therapy The combination of POM with LoDEX improves the ORR due to synergy between immunomodulatory agents and glucocorticoids POM + LoDEX, 34%; POM alone, 15% Response was durable with POM regardless of the addition of LoDEX POM + LoDEX, 8.3 months ; POM alone, 8.8 months POM is generally well tolerated, with low rates of discontinuations due to AEs Age had no impact on ORR, DoR, or safety Jagannath S, et al. Blood. 2012;120:abstract 450. Pomalidomide Plus Low-Dose Dexamethasone (Pom/Dex) in Relapsed Myeloma (345 patients) Pom/Dex has high response rates even in heavily pretreated relapsed myeloma Pom/Dex is well tolerated Toxicity and efficacy are similar between the 2mg and 4mg dose levels The strongest predictors of response include the number and type of prior regimens. The strongest predictors of TTP and survival include the number and type of prior regimens, LDH, and B2M. Lacy et al ASH 2013 Abstr 201
17 A Phase III Clinical Trial of Pomalidomide with Low-Dose Dex vs High Dose Dex in Relapsed/Refractory MM POM + LoDEX significantly improved PFS and OS Median PFS: 3.6 vs 1.8 months HR = 0.45; P <.001 Median OS: not reached vs 7.8 months HR = 0.53; P <.001 Equal benefit in pts refractory to both LEN and BORT POM + LoDEX was generally well tolerated POM + LoDEX should be considered as a new treatment option for these pts Dimopoulos et al ASH 2013 LBA6 MM-005: A Phase 1 Trial of Pomalidomide, Bortezomib,, and Low-Dose Dexamethasone in Relapsed or Relapsed/Refractory MM POM + BORT + LoDEX (PVD) well tolerated cohort 5 as the MTD/MPD POM 4 mg; BORT 1.3 mg/m 2 ; DEX 10/20 mg Responses in RR MM across all cohorts ORR: 73%, VGPR: 27%, SD: 27% Responses were rapid; majority are ongoing Efficacy even with adverse cytogenetics Phase III Trial Pom Bort Dex vs Bort Dex for full approval Richardson et al, ASH 2013 Abstr 727
18 Carfilzomib in Relapsed/Refractory MM Study Ph BTZ status n PX 171 II Relapsed and 003 A1 1 refractory Median prior tx lines CFZ dose Mode of admin /27 mg/m min IV infusion ORR 24% PX 171 I/II Relapsed and/or refractory /56 mg/m 2 30 min IV infusion 60% 1. Siegel et al. Blood. 2012;120(14): Papadopoulos KP, et al. Blood. 2011;118(21):Abstract and poster Phase II Study of Infusional Carfilzomib in Patients with Relapsed or Refractory MM CFZ dose of 20/56 mg/m 2 administered as a 30 minute IV infusion resulted in high response rates in our BTZ treated/refractory population. Response rates were comparable to those seen in PX CFZ dose of 20/56 mg/m 2 was associated with more frequent cardiac and pulmonary toxicities, particularly HTN and pulmonary edema/chf. Possible contribution from supportive measures? CFZ dose of 20/56 mg/m 2 continues to be explored in ongoing Phase II/III studies. Lendvai et al, ASH 2013 Abstr
19 Carfilzomib Pomalidomide Dexamethasone (Car-Pom Pom-d) ) in Relapsed/Refractory MM MTD was Carfilzomib 20/27 mg/m 2, Pomalidomide 4 mg, and dexamethasone 40 mg There are limited G 3 and 4 non hematologic toxicities; the regimen was tolerated well with no unexpected toxicity The combination of Car-Pom d is highly active in this heavily pretreated, refractory patient population VGPR 13% ORR 50% CBR 67% PFS (median) 7.4 months OS 1 year The combination has encouraging preserved response rate and survival independent of FISH/cytogenetic risk status Shah et al ASH 2013 Abstr 74 MAb-Based Therapeutic Targeting of Myeloma Antibody-dependent Cellular cytotoxicity (ADCC) Complement-dependent Cytotoxicity (CDC) C1q Apoptosis/growth arrest via targeting signaling pathways Effector cells: CDC C1q ADCC FcR MM MM MM Daratumumab (CD38) Lucatumumab or Dacetuzumab (CD40) Elotuzumab (CS1) Daratumumab (CD38) XmAb 5592 (HM1.24) hun901-dm1 (CD56) nbt062-maytansinoid (CD138) 1339 (IL-6) BHQ880 (DKK1) RAP-011 (activin A) Daratumumab (CD38) Tai & Anderson Bone Marrow Research 2011
20 A Phase 2 Study of Elotuzumab with Lenalidomide and Low-Dose Dex in Relapsed/ Refractory MM Elotuzumab plus lenalidomide and low-dose dexamethasone has a high ORR in relapsed and relapsed/refractory MM* ASH 2012 ORR 84% for the study as a whole, with ORR 92% for pts treated with elotuzumab 10mg/kg ORR 91% in pts who had received only 1 prior therapy Median PFS for elotuzumab 10mg/kg + Len/dex was not yet reached (median follow-up of 20.8 months)* median PFS: 29.7 months for pts treated with 1 prior therapy Elotuzumab + Len/dex was generally well tolerated at both the 10 and 20 mg/kg doses most common Grade 3/4 treatment-emergent AEs : lymphopenia (19%), neutropenia (18%), and thrombocytopenia (16%). Richardson et al ASH 2013 Abstr Daratumumab A human CD38 mab with broad-spectrum killing activity Lokhorst et al EHA
21 PHASE I/II STUDY OF DARATUMUMAB CD38 MONOCLONAL ANTIBODY IN RELAPSED/REFRACTORY MM Favorable safety profile as monotherapy In 15 of 32 (47%) showed benefit 4 patients achieving PR (13%) 6 patients achieving MR (19%) 5 patients achieving SD (16%) At doses 4mg/kg and above, 8 of the 12 patients had at least MR (66%) To be combined with lenalidomide dexamethasone Plesner et al ASH 2013 Abstr Factors impacting QOL Peripheral Neuropathy Cytopenia DVT Fatigue Herpes Zoster (Shingles) Bone Disease
22 Management of Peripheral Neuropathy Prompt Dose Reduction Schedule Change Discontinuation when PN emerges Use of Supplements Symptom Relief Pain medication Anti-depressants Gabapentin, Pregabalin, Duloxitin Prophylaxis and Treatment Multi-B Complex Vitamins Vitamin E Vitamin D Fish Oils Magnesium Potassium Tonic Water Acetyl L-Carnitine Alpha-Lipoic Acid Glutamine Cocoa Butter With B1, B6, B12, folic acid and other B6 should be approximately 50mg daily, not to exceed 100mg per day. Folic acid should be 1mg per day 400 IU daily IU daily OMEGA-3 Fatty Acids (EPA and DHA) Suggested doses include: 250mg twice a day (OTC). Alternatively 400mg daily by prescription with dose frequency dependent on serum Magnesium levels. May cause diarrhea in larger doses Either as provided by the treating physician or foods that are rich in potassium (eg bananas, oranges and potato). Drink one glass in evening and any other time cramping occurs 500mg twice a day with food. Can take up to 2000mg a day. 300mg to 1000mg a day with food 1g up to three times a day with food Apply to affected areas twice a day with gentle massage (rich in xanthenes, serotonins, Vitamin E and other emollients) Menthol Based Creams Apply to areas of numbness twice daily with gentle massage (e.g. Vick s Vapo-Rub) ** Do not take supplements on days of bortezomib infusions 1. Richardson PG et al, JNCCN 2010; 8: S4-S Perrone G, et al. Leukemia. 2009;23(9): Cately L, et al. Clin Cancer Res. 2006;12: Kim TY et al. Br J Haematol. 2009;146(3):
23 Drug-induced cytopenia Bortezomib Lenalidomide Chemotherapeutic agents Combinations Causes of Cytopenia Disease Bone marrow infiltration Drug effect Poor recovery from transplant Burnt out marrow
24 Fatigue Etiology: Disease-related cytokine (IL-6), Hyperviscocity Anemia Treatment-related - Thalidomide, bortezomib, lenalidomide Hypoadrenalism Hypogonadism Depression Some ideas to combat fatigue: short naps in the afternoon, healthy diet, plenty of fluid, exercise, try to stay active with friends and family. Discuss with healthcare team if fatigue is interfering with daily living. Treat the cause Herpes Zoster Prophylaxis With Bortezomib Treatment Immunocompromized pts at risk of developing VZV infection Bortezomib is associated with increased risk of VZV infection [1] Acyclovir and other antiviral prophylaxis appear effective at preventing VZV infection in patients treated with bortezomib for MM (with or without corticosteroids) [2] Vaccine not recommended at present 1. Chanan-Khan AA, et al. J Clin Oncol. 2008;26: Vickrey E, et al. Cancer. 2009;115:
25 ASCO Clinical Practice Guidelines for Bone Disease Bisphosphonates Indicated for MM pts w/ lytic bone disease osteopenia Useful as an adjunct for pts w/ bone pain The bisphosphonates recommended are either Zoledronic acid: 4 mg over 15 mins, IV q 3-4 wks Pamidronate: 90 mg over > 2 hrs, IV q 3-4 wks Monitoring w/ serum creatinine (both BPs) and/or urine albumin (for palmidronate only) PAM preferred in setting of renal dysfunction Re-evaluate after 2 years and consider stopping if stable disease Kyle R, et al. JCO : Summary of ASH Use of novel agents as initial, maintenance, and relapsed/refractory therapy 2. Second generation proteasome inhibitors and imids. 3. Development of novel combination therapies 4. Monoclonal antibody therapies 5. Treatment of side effects
26
27
Treatment of elderly multiple myeloma patients
SAMO Interdisciplinary Workshop on Myeloma March 30 th -31 st 2012, Seehotel Hermitage, Lucerne Treatment of elderly multiple myeloma patients Federica Cavallo, MD, PhD Federica Cavallo, MD, PhD Division
More informationStandard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant
Standard of care for patients with newly diagnosed multiple myeloma who are not eligible for a transplant Pr Philippe Moreau University Hospital, Nantes, France MP: Standard of care until 2007 J Clin Oncol
More informationHow to Integrate the New Drugs into the Management of Multiple Myeloma
How to Integrate the New Drugs into the Management of Multiple Myeloma Carol Ann Huff, MD The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins NCCN.org For Clinicians NCCN.org/patients For Patients
More informationTo Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors
To Maintain or Not to Maintain? Immunomodulators vs PIs Yes: Proteasome Inhibitors James Berenson, MD Institute for Myeloma and Bone Cancer Research West Hollywood, CA Financial Disclosures Takeda, Celgene
More informationMyeloma update ASH 2014
Myeloma update ASH 2014 Updates in Newly Diagnosed Multiple Myeloma FIRST: effect of age on lenalidomide/dexamethasone vs MPT in transplantation-ineligible pts Phase III: MPT-T vs MPR-R in transplantation-ineligible
More informationNovel Combination Therapies for Untreated Multiple Myeloma
Novel Combination Therapies for Untreated Multiple Myeloma Andrzej J. Jakubowiak, MD, PhD Director, Myeloma Program New York, NY, October 27, 201 Disclosures 2 Employee Consultant Major Stockholder Speakers
More informationCME Information LEARNING OBJECTIVES
CME Information LEARNING OBJECTIVES Identify patients with MM who have undergone autologous stem cell transplant and would benefit from maintenance lenalidomide. Counsel older patients (age 65 or older)
More informationMultiple Myeloma: ASH 2008
Multiple Myeloma: ASH 2008 Steven Coutre, M.D. Associate Professor of Medicine Division of Hematology Stanford University School of Medicine About These Slides These slides accompany CCO s comprehensive
More informationInitial Therapy For Transplant-Eligible Patients With Multiple Myeloma. Michele Cavo, MD University of Bologna Bologna, Italy
Initial Therapy For Transplant-Eligible Patients With Multiple Myeloma Michele Cavo, MD University of Bologna Bologna, Italy Treatment Paradigm for Autotransplant-Eligible Patients With Multiple Myeloma
More informationConsolidation and maintenance therapy for transplant eligible myeloma patients
Consolidation and maintenance therapy for transplant eligible myeloma patients Teeraya Puavilai, M.D. Division of Hematology, Department of Medicine Faculty of Medicine Ramathibodi Hospital Mahidol University
More informationPomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma. Lacy MQ et al. J Clin Oncol 2009;27(30):
Pomalidomide (CC4047) Plus Low-Dose Dexamethasone as Therapy for Relapsed Multiple Myeloma Lacy MQ et al. J Clin Oncol 2009;27(30):5008-14. Introduction A curative therapy for multiple myeloma (MM) does
More informationDisclosures for Palumbo Antonio, MD
Disclosures for Palumbo Antonio, MD Research Support/P.I. Employee Consultant Major Stockholder Speakers Bureau Honoraria Scientific Advisory Board o relevant conflicts of interest to declare o relevant
More informationDevelopments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D.
Developments in the Treatment of Multiple Myeloma Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center Dana-Farber Cancer
More informationTreatment of elderly patients with multiple myeloma
Treatment of elderly patients with multiple myeloma Mario Boccadoro DIVISIONE UNIVERSITARIA DI EMATOLOGIA AZIENDA OSPEDALIERA SAN GIOVANNI TORINO, ITALY Improved survival in multiple myeloma and the impact
More informationMichel Delforge Belgium. New treatment options for multiple myeloma
Michel Delforge Belgium New treatment options for multiple myeloma Progress in the treatment of MM over the past 40 years 1962 Prednisone + melphalan 1990s Supportive care 1999 First report on thalidomide
More informationOncology Highlights ASCO 2011 MULTIPLE MYELOMA
Oncology Highlights ASCO 211 MULTIPLE MYELOMA July 211 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael, MD, MEd, FRCPC Staff Hematologist, Mayo Clinic Arizona Disclosures
More informationCOMy Congress The case for IMids. Xavier Leleu. Hôpital la Milétrie, PRC, CHU, Poitiers, France
Xavier Leleu Hôpital la Milétrie, PRC, CHU, Poitiers, France The case for IMids COMy Congress 21 Disclosures Grants/research support: Amgen, Bristol-Myers Squibb, Celgene, Janssen, Millennium/Takeda, Novartis,
More informationMultiple Myeloma Brian Berryman, M.D. March 8 th, 2014
Multiple Myeloma 2014 Brian Berryman, M.D. March 8 th, 2014 Kyle, R. A. et al. Blood 2008;111:2962-2972 Updates in Multiple Myeloma CCO Independent Conference Coverage of the 2013 Annual Meeting of
More informationIs autologous stem cell transplant the best consolidation after initial therapy?
Is autologous stem cell transplant the best consolidation after initial therapy? William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director,
More informationProgress in Multiple Myeloma
Progress in Multiple Myeloma Sundar Jagannath, MD Professor, New York Medical College Adjunct Professor, New York University St. Vincent s Comprehensive Cancer Center, NY Faculty Disclosure Advisory Board:
More informationIMiDs (Immunomodulatory drugs) and Multiple Myeloma
www.comtecmed.com/comy comy@comtecmed.com IMiDs (Immunomodulatory drugs) and Multiple Myeloma Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France www.comtecmed.com/comy comy@comtecmed.com
More informationNew Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D.
New Drugs on the Horizon Providing Hope for Multiple Myeloma Patients Kenneth C. Anderson, M.D. Kraft Family Professor of Medicine Harvard Medical School Director, Jerome Lipper Multiple Myeloma Center
More informationHow I Treat Transplant Eligible Myeloma Patients
How I Treat Transplant Eligible Myeloma Patients Michele Cavo Seràgnoli Institute of Hematology, Bologna University School of Medicine, Italy Podcetrtek, Slovene, April 14 th, 2012 NEW TREATMENT PARADIGM
More informationTo Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York
To Maintain or Not to Maintain? Lymphoma and Myeloma 2015 Waldorf Astoria Hotel, New York Sundar Jagannath Director, Multiple Myeloma Program Tisch Cancer Institute Mount Sinai Medical Center Maintenance
More informationRole of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach
Role of Maintenance and Consolidation Therapy in Multiple Myeloma: A Patient-centered Approach Jacob Laubach, MD Assistant Professor in Medicine Harvard Medical School Clinical Director of the Jerome Lipper
More informationUnmet Medical Needs and Latest Multiple Myeloma Treatment
Unmet Medical Needs and Latest Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director
More informationRole of consolidation therapy in Multiple Myeloma. Pieter Sonneveld. Erasmus MC Cancer Institute Rotterdam The Netherlands
Role of consolidation therapy in Multiple Myeloma Pieter Sonneveld Erasmus MC Cancer Institute Rotterdam The Netherlands Disclosures Research support : Amgen, Celgene, Janssen, Karyopharm Advisory Boards/Honoraria:
More informationCREDIT DESIGNATION STATEMENT
CME Information LEARNING OBJECTIVES Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance
More informationMultiple Myeloma Updates 2007
Multiple Myeloma Updates 2007 Brian Berryman, M.D. Multiple Myeloma Updates 2007 Goals for today: Understand the staging systems for myeloma Understand prognostic factors in myeloma Review updates from
More informationLiving Well with Myeloma Teleconference Series Thursday, March 24 th :00 PM Pacific/5:00 PM Mountain 6:00 PM Central/7:00 PM Eastern
Living Well with Myeloma Teleconference Series Thursday, March 24 th 216 4: PM Pacific/5: PM Mountain 6: PM Central/7: PM Eastern Speakers Dr. Brian Durie, IMF Chairman Cedars Sinai Samuel Oschin Cancer
More informationUpdate on Multiple Myeloma Treatment
Update on Multiple Myeloma Treatment Professor Chng Wee Joo Director National University Cancer Institute of Singapore (NCIS) National University Health System (NUHS) Deputy Director Cancer Science Institute,
More informationChristine Chen Princess Margaret Cancer Centre September 2013
Christine Chen Princess Margaret Cancer Centre September 2013 Disclosures Research Support Celgene, Janssen, GSK Employee N/A Consultant N/A Major Stockholder Speakers Bureau/ Scientific Advisory Board
More informationManagement of Multiple
Management of Multiple Myeloma in the Elderly Xavier Leleu Service des Maladies du Sang Hôpital Huriez, CHRU, Lille, France INSERM U837, équipe 3 IRCL, CHRU, Lille, France IMPRT Institut de Médecine Prédictive
More informationDisclosures. Consultancy, Research Funding and Speakers Bureau: Celgene Corporation, Millennium, Onyx, Cephalon
Pomalidomide With or Without Low-dose Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma: Outcomes in Patients Refractory to Lenalidomide and Bortezomib Ravi Vij 1, Paul G. Richardson
More informationTreatment Strategies for Transplant-ineligible NDMM Patients
1 Treatment Strategies for Transplant-ineligible NDMM Patients Thierry Facon, MD Professor of Hematology Service des Maladies du Sang University of Lille Lille, France Multiple Myeloma affects primarily
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (D) vs Bortezomib and Dexamethasone () in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationInduction Therapy: Have a Plan. Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program
Induction Therapy: Have a Plan Sagar Lonial, MD Professor, Winship Cancer Institute Director of Translational Research, B-cell Malignancy Program Topics When to treat? Smoldering vs Symptomatic Risk stratification
More informationRisk stratification in the older patient; what are our priorities?
Risk stratification in the older patient; what are our priorities? Sonja Zweegman MD PhD Amsterdam The Netherlands Negative impact of age on survival Meta-analysis of European trials (MP vs MPT, VMP vs
More informationTREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE
TREATING RELAPSED / REFRACTORY MYELOMA AT THE LEADING EDGE PRESENTED BY: Pooja Chaukiyal MD Hematologist/Oncologist New York Oncology Hematology Albany, NY April 16, 2016 Background The prognosis for patients
More informationMultiple myeloma, 25 (45) years of progress. The IFM experience in patients treated with frontline ASCT. Philippe Moreau, Nantes
Multiple myeloma, 25 (45) years of progress The IFM experience in patients treated with frontline ASCT Philippe Moreau, Nantes Shibata T. Prolonged survival in a case of multiple myeloma treated with high
More informationProteasome inhibitor (PI) and immunomodulatory drug (IMiD) refractory multiple myeloma is associated with inferior patient outcomes
Alliance A061202. A phase I/II study of pomalidomide, dexamethasone and ixazomib versus pomalidomide and dexamethasone for patients with multiple myeloma refractory to lenalidomide and proteasome inhibitor
More informationSmoldering Myeloma: Leave them alone!
Smoldering Myeloma: Leave them alone! David H. Vesole, MD, PhD Co-Director, Myeloma Division Director, Myeloma Research John Theurer Cancer Center Hackensack University Medical Center Prevalence 1960 2002
More informationPost Transplant Maintenance- for everyone? Disclosures
Post Transplant Maintenance- for everyone? NO Because of limited survival data, not all patients require maintenance April 2012 Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Joseph Mikhael,
More informationChoosing upfront and salvage therapy for myeloma in the ASEAN context
Choosing upfront and salvage therapy for myeloma in the ASEAN context Daryl Tan Consultant Department of Haematology Singapore General Hospital Adjunct Assistant Professor Duke-NUS Graduate Medical School
More informationTerapia del mieloma. La terapia di prima linea nel paziente giovane. Elena Zamagni
Terapia del mieloma La terapia di prima linea nel paziente giovane Elena Zamagni Istituto di Ematologia ed Oncologia Medica Seràgnoli Università degli Studi di Bologna Newly diagnosed MM Candidate for
More informationA Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma
A Multi-Center Phase I/II Trial of Carfilzomib and Pomalidomide with Dexamethasone (Car- Pom-d) in Patients with Relapsed/Refractory Multiple Myeloma Jatin J. Shah, MD 1, Edward A. Stadtmauer, MD 2, Rafat
More informationCurrent Management of Multiple Myeloma. December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C.
Current Management of Multiple Myeloma December 2012 Kevin Song MD FRCPC Leukemia/BMT Program of B.C. Disclosures Honoraria Speaker Celgene, Janssen, Novartis Celgene, Janssen Research Support Celgene
More informationDisclosures. Membership of Advisory Committees: Research Support/ PI: Celgene Corporation Millennium Pharmaceuticals Johnson & Johnson
Randomized, Open-Label Phase 1/2 Study of Pomalidomide Alone or in Combination With Low-Dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma Who Have Received Prior Treatment That
More informationConsolidation and Maintenance therapy
University of Salamanca Consolidation and Maintenance therapy María-Victoria Mateos, MD, PhD University Hospital of Salamanca, Spain Disclosure form MVM has served as member of advisory boards or received
More informationManaging Newly Diagnosed Multiple Myeloma
Managing Newly Diagnosed Multiple Myeloma 26 Jan 2018 Alfred Garfall, MD Assistant Professor of Medicine Diagnosis of Multiple Myeloma Traditional criteria: Monoclonal plasma cells + attributable CRAB
More informationIntegration of Novel Therapy Into Myeloma Management
Updates on Diagnostic Criteria and Management of Multiple Myeloma Kenneth C. Anderson, MD Dana-Farber Cancer Institute Integration of Novel Therapy Into Myeloma Management Bortezomib, lenalidomide, thalidomide,
More informationShould we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain
Should we treat Smoldering MM patients? María-Victoria Mateos University Hospital of Salamanca Salamanca. Spain Should we treat some patients with Stage I MM? Len-dex is a promising and atractive option
More informationTREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA
TREATMENT FOR NON-TRANSPLANT ELIGIBLE MULTIPLE MYELOMA Ekarat Rattarittamrong, MD Division of Hematology Department of Internal Medicine Faculty of Medicine Chiang Mai University OUTLINE Overview of treatment
More informationApproach to the Treatment of Newly Diagnosed Multiple Myeloma. S. Vincent Rajkumar Professor of Medicine Mayo Clinic
Approach to the Treatment of Newly Diagnosed Multiple Myeloma S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic College of
More informationMultiple Myeloma: Induction, Consolidation and Maintenance Therapy
Multiple Myeloma: Induction, Consolidation and Maintenance Therapy James R. Berenson, MD Medical & Scientific Director Institute for Myeloma & Bone Cancer Research Los Angeles, CA Establish the Goals of
More informationClinical Case Study Discussion: Maintenance in MM
www.comtecmed.com/comy comy@comtecmed.com Evangelos Terpos, MD, PhD National & Kapodistrian University of Athens, School of Medicine, Athens, Greece Clinical Case Study Discussion: Maintenance in MM Disclosure
More informationIl trattamento del Mieloma su stratificazione di rischio: è oggi possibile?
Il trattamento del Mieloma su stratificazione di rischio: è oggi possibile? Francesca Gay, MD Divisione Ematologia 1 AO Città della Salute e della Scienza, Torino, Italy Focus sul MM 2014 Cagliari, 30-31
More informationHighlights from EHA Mieloma Multiplo
Highlights from EHA Mieloma Multiplo Michele Cavo Istituto di Ematologia L. e A. Seràgnoli Alma Mater Studiorum Università degli studi di Bologna Firenze, 22-23 Settembre 27 Myeloma XI TE pathway 7 R :
More informationMaintenance therapy after autologous transplantation
Maintenance therapy after autologous transplantation Sonja Zweegman MD PhD Department of Hematology Amsterdam The Netherlands Disclosures Research funding from Celgene, Takeda and Janssen Participation
More informationCuring Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham
Curing Myeloma So Close and Yet So Far! Luciano J. Costa, MD, PhD Associate Professor of Medicine University of Alabama at Birmingham What is cure after all? Getting rid of it? Stopping treatment without
More informationExperience with bortezomib (Velcade) in multiple myeloma. Peter Černelč Clinical center Ljubljana Department of Haematology
Experience with bortezomib (Velcade) in multiple myeloma Peter Černelč Clinical center Ljubljana Department of Haematology Our experience with bortezomib (Velcade) in multiple myeloma 1. Our first experience
More informationMultiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D.
Multiple Myeloma What is New? Can we talk cure? Rafat Abonour, M.D. Multiple Myeloma Facts Second most prevalent hematologic neoplasm Nearly 24, new cases diagnosed in the US per year and 11, worldwide
More informationContinuous Therapy as a Standard of Care CON. JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France
Continuous Therapy as a Standard of Care CON JL Harousseau Institut de Cancérologie de l Ouest Nantes Saint Herblain France 1 In France and in the IFM all debates 2 In France and in the IFM all debates
More informationTreatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice
Treatment Advances in Multiple Myeloma: Expert Perspectives on Translating Clinical Data to Practice Friday, December 2, 2016 San Diego, California This program is supported by educational grants from
More informationMULTIPLE MYELOMA. TREATMENT in 2017 MC. VEKEMANS
MULTIPLE MYELOMA TREATMENT in 2017 MC. VEKEMANS NATURAL HISTORY of MM WHO SHOULD BE TREATED? DEFINITION MGUS Smouldering Multiple Myeloma Symptomatic Multiple Myeloma Monoclonal component (blood and/or
More informationInduction Therapy in Transplant Eligible MM 2 December Tontanai Numbenjapon, M.D.
Induction Therapy in Transplant Eligible MM 2 December 2017 Tontanai Numbenjapon, M.D. What we need from induction therapy in NDMM Depth of response: MRD-negative, scr, CR Longest response Acceptable toxicity
More informationOvercoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma
Overcoming Current Challenges in the Management of De Novo and Relapsed/Refractory Multiple Myeloma George Somlo M.D. City of Hope Comprehensive Cancer Center The Cause 1 Myeloma: Clinical Features Bone
More informationMultiple Myeloma: Miami, FL Current Treatment Paradigms and Future Directions December 18, 2009
Welcome to Master Class for Oncologists Miami, FL December 18, 29 Session 5: 11: AM - 11:45 AM Multiple Myeloma: Current Treatment Paradigms and Future Directions Speaker: Kenneth C. Anderson, MD Chief,
More informationA Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma
A Phase 1 Trial of Lenalidomide (REVLIMID ) With Bortezomib (VELCADE ) in Relapsed and Refractory Multiple Myeloma P.G. Richardson, 1 R. Schlossman, 1 N. Munshi, 1 D. Avigan, 2 S. Jagannath, 3 M. Alsina,
More informationRegimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone
Regimen Protocols IRD or RID: Ixazomib citrate/lenalidomide/dexamethasone Constituents of Regimen: ixazomib, lenalidomide, dexamethasone Other Names of Regimen Constituents and Unique Ingredient Identifier
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationDana-Farber Cancer Institute, Boston, MA, USA; 2. H. Lee Moffitt Cancer Center & Research Institute, Tampa, FL, USA; 3
The investigational agent MLN9708, an oral proteasome inhibitor, in patients with relapsed and/or refractory multiple myeloma (MM): results from the expansion cohorts of a phase 1 dose-escalation study
More informationTiming of Transplant for Multiple Myeloma
Timing of Transplant for Multiple Myeloma Wenming CHEN Beijing Chaoyang Hospital Capital Medical University Multiple myeloma resrarch center of Beijing Initial Approach to Treatment of Myeloma Nontransplantation
More informationMultiple Myeloma: Diagnosis and Primary Treatment
Multiple Myeloma: Diagnosis and Primary Treatment George Somlo, MD City of Hope Comprehensive Cancer Center NCCN.org For Clinicians NCCN.org/patients For Patients Educational Objectives Discuss considerations
More informationCurrent management of multiple myeloma. Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School
Current management of multiple myeloma Jorge J. Castillo, MD Assistant Professor of Medicine Harvard Medical School JorgeJ_Castillo@dfci.harvard.edu Multiple myeloma MM is a plasma cell neoplasm characterized
More informationMYELOMA MAINTENANCE BEST PRACTICES:
MYELOMA MAINTENANCE BEST PRACTICES: POST THERAPY & POST TRANSPLANT Aric Hall, MD Assistant Professor University of Wisconsin Hospital and Clinics INTRODUCTION MYELOMA Clonal plasma cell malignancy leading
More informationConsolidation after Autologous Stem Cell Transplantion
Consolidation after Autologous Stem Cell Transplantion Joan Bladé Laura Rosiñol Department of Hematology Hospital Clínic de Barcelona Berlin, September 11 th 2011 Autologous Stem Cell Transplant in Younger
More informationUpfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum
Upfront Therapy for Myeloma Tailoring Therapy across the Disease Spectrum S. Vincent Rajkumar Professor of Medicine Mayo Clinic Scottsdale, Arizona Rochester, Minnesota Jacksonville, Florida Mayo Clinic
More informationManaging Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient. Case Study
Managing Myeloma Virtual Grand Rounds Newly Diagnosed, Transplant Eligible Patient Case Study 2 2011 Newly Diagnosed Patient The patient is a 61-year-old Caucasian female History of high blood pressure
More informationUpdates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma
Updates in the Treatment and Management of Relapsed/Refractory Multiple Myeloma Rachid Baz, MD Associate Professor, Departments of Oncologic Sciences and Medicine University of South Florida Associate
More informationNovel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors
Novel treatment strategies for multiple myeloma: a focus on oral proteasome inhibitors Antonio Palumbo M.D. Takeda Pharmaceuticals International AG Introduction Multiple genetically-distinct subclones
More informationPhase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM)
Phase 1 Study of ARRY-520 and Carfilzomib in Patients With Relapsed/Refractory Multiple Myeloma (RRMM) Jatin J Shah, MD, Sheeba Thomas, MD, Donna Weber, MD, Michael Wang, MD, Raymond Alexanian, MD, Robert
More informationHighlights in multiple myeloma
3 CONGRESS HIGHLIGHTS Highlights in multiple myeloma P. Vlummens, MD SUMMARY Multiple myeloma (MM) remains a devastating disease, even in the era of novel agents. As such, the search for new treatment
More informationASCO Analyst & Investor Webcast. June 1, 2018
ASCO Analyst & Investor Webcast June 1, 2018 June 1, 2018 NASDAQ: BLUE Forward Looking Statements These slides and the accompanying oral presentation contain forward-looking statements and information
More informationPhase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma
Phase I/II Trial of the Combination of Lenalidomide, Thalidomide and Dexamethasone In Relapsed/Refractory Multiple Myeloma Jatin J Shah, MD 1, Robert Z. Orlowski, MD, PhD 1, Raymond Alexanian, MD 1, Michael
More informationH. Lee Moffitt Cancer Center and Research Institute, University of California, San Francisco & Tisch Cancer Institute, Mount Sinai School of Medicine
Pomalidomide, Cyclophosphamide, and Dexamethasone Is Superior to Pomalidomide and Dexamethasone in Relapsed and Refractory Myeloma: Results of a Multicenter Randomized Phase II Study Rachid Baz, Thomas
More informationAutologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011
Autologous Stem Cell Transplanation as First line Treatment? (Against) Joan Bladé Berlin, September 9 th, 2011 Significant impact of ASCT before the availability of novel agents? Randomized trials: Single
More informationNovel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma
Novel Treatment Advances and Approaches in Management of Relapsed/Refractory Multiple Myeloma Ravi Vij, MD MBA Professor of Medicine Washington University School of Medicine Section of Stem Cell Transplant
More informationConflict of Interest Disclosure Form
Conflict of Interest Disclosure Form NAME : Niels van de Donk MD-PhD AFFILIATION: University of California San Francisco. In accordance with the rules of the Health Care Inspectorate (IGZ), speakers are
More informationAntibodies are a standard part of first relapse management in multiple myeloma (MM): Yes
Antibodies are a standard part of first relapse management in multiple myeloma (MM): Yes Ajay Nooka, MD MPH FACP Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory
More informationMAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA. Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health
MAINTENANCE AND CONTINUOUS THERAPY OF MYELOMA Myeloma Day 11/18/2017 Aric Hall, MD Assistant Professor UW School of Medicine & Public Health Disclosures I have no significant conflicts of interest to disclose.
More informationDaratumumab: Mechanism of Action
Phase 3 Randomized Controlled Study of Daratumumab, Bortezomib and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Patients with Relapsed or Refractory Multiple Myeloma (RRMM): CASTOR* Antonio
More informationManagement of Multiple Myeloma: The Changing Paradigm
Management of Multiple Myeloma: The Changing Paradigm High-Dose Chemotherapy and Stem Cell Transplantation Todd Zimmerman, MD University of Chicago Medical Center Case Presentation R.M. is a 64 year old
More informationGetting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions
Getting Clear Answers to Complex Treatment Challenges in Multiple Myeloma: Case Discussions Friday, December 8, 2017 Atlanta, Georgia Friday Satellite Symposium preceding the 59th ASH Annual Meeting &
More informationAutologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy
Autologous Stem Cell Transplantation in Multiple Myeloma Optimal Frontline Therapy and Maintenance Therapy Donna E. Reece, M.D. Princess Margaret Hospital Toronto, ON CANADA 10 December 2011 ASCT in Myeloma..
More informationMillennium Pharmaceuticals, Inc., Cambridge, MA; 11 Dana-Farber Cancer Institute, Boston, MA
Phase 1/2 study of weekly MLN9708, an investigational oral proteasome inhibitor, in combination with lenalidomide and dexamethasone in patients with previously untreated multiple myeloma Shaji K. Kumar,
More informationInduction Therapy & Stem Cell Transplantation for Myeloma
Induction Therapy & Stem Cell Transplantation for Myeloma William Bensinger, MD Professor of Medicine, Division of Oncology University of Washington School of Medicine Director, Autologous Stem Cell Transplant
More informationRecent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma.
Recent Advances in the Treatment & Management of Relapsed Refractory Multiple Myeloma. Ajay Nooka MD MPH Assistant Professor, Division of Bone Marrow Transplant Winship Cancer Institute, Emory University
More informationMULTIPLE MYELOMA AFTER AGE OF 80 YEARS
MULTIPLE MYELOMA AFTER AGE OF 80 YEARS C. Hulin CHU Nancy, France Intergroupe Francophone du Myelome (IFM) Epidemiology SEER Program between 1990-2004: 17 330 MM cases, 51% 70 y and 20% 80 y. Brenner et
More information